Details of Drug-Drug Interaction
| Drug General Information (ID: DDIABO7EW3) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Amikacin (liposome) | Drug Info | Pancuronium | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antibiotics | Neuromuscular Blocking Agents | |||||||
| Structure | |||||||||
| Mechanism of Amikacin (liposome)-Pancuronium Interaction (Severity Level: Major) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive neuromuscular blocking effects Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Amikacin (liposome) | Pancuronium | |||||||
| Mechanism |
Neuromuscular blocking effects Aminoglycosides |
Neuromuscular blocking agent Neuronal acetylcholine receptor Antagonist |
|||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Neuronal acetylcholine receptor | Structure Sequence | |||||||
| Protein Family | Ligand-gated ion channel (TC 1.A.9) family | ||||||||
| Protein Function |
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Click to Show/Hide
|
||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | The use of aminoglycosides should generally be avoided during and immediately after surgery in which neuromuscular blockers have been employed. If these agents are used concurrently, vital signs should be closely monitored and drug dosages adjusted accordingly. In addition, ventilatory support should be readily available in case of respiratory arrest. Treatment with anticholinesterases and calcium may not always be effective in reversing the neuromuscular blockade caused by these agents. | ||||||||